Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

K. Petráková · SciRah

Researcher profile · Semantic Scholar

K. Petráková

Share profile

K. Petráková — researcher profile on SciRah

h-index: 32
Works: 109
Citations: 10K

Most-cited papers

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
G. Hortobagyi, S. Stemmer, H. Burris, Y. Yap +33 more
2016New England Journal of Medicine1,684 citations Open access
Semantic Scholar
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
J. Cortés, J. O'Shaughnessy, D. Loesch, J. Blum +16 more
2011The Lancet996 citations
Semantic Scholar
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
D. Slamon, P. Neven, S. Chia, P. Fasching +17 more
2018Journal of Clinical Oncology952 citations
Semantic Scholar
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
G. Hortobagyi, S. Stemmer, H. Burris, Y. Yap +17 more
2018Annals of Oncology755 citations Open access
Semantic Scholar
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
D. Slamon, P. Neven, S. Chia, P. Fasching +17 more
2019New England Journal of Medicine692 citations Open access
Semantic Scholar
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
G. Hortobagyi, S. Stemmer, H. Burris, Y. Yap +16 more
2022New England Journal of Medicine644 citations Open access
Semantic Scholar
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Miguel Martín, F. Holmes, B. Ejlertsen, S. Delaloge +496 more
2017The Lancet Oncology512 citations
Semantic Scholar
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
A. Chan, S. Delaloge, F. Holmes, B. Moy +26 more
2016The Lancet Oncology499 citations
Semantic Scholar
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
D. Yardley, S. Noguchi, K. Pritchard, Howard A. Iii Burris +16 more
2013Advances in Therapy496 citations Open access
Semantic Scholar
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer
H. Rugo, S. Im, F. Cardoso, J. Cortés +26 more
2021JAMA Oncology275 citations Open access
Semantic Scholar
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
I. Krop, I. Mayer, V. Ganju, M. Dickler +20 more
2016The Lancet Oncology268 citations Open access
Semantic Scholar
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase 3 randomized MONALEESA-3 trial: updated overall survival.
D. Slamon, P. Neven, S. Chia, G. Jerusalem +16 more
2021Annals of Oncology255 citations Open access
Semantic Scholar
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
E. Mittendorf, B. Lu, M. Melisko, Julie Price-Hiller +5 more
2019Clinical Cancer Research155 citations
Semantic Scholar
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
P. Vuylsteke, M. Huizing, K. Petráková, R. Roylance +9 more
2016Annals of Oncology111 citations Open access
Semantic Scholar
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
J. O'Shaughnessy, K. Petráková, G. Sonke, P. Conte +11 more
2017Breast Cancer Research and Treatment105 citations Open access
Semantic Scholar
Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial
H. Burris, F. Lebrun, H. Rugo, J. T. Beck +16 more
2013Cancer103 citations Open access
Semantic Scholar
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant
P. Neven, P. Fasching, S. Chia, G. Jerusalem +14 more
2023Breast Cancer Research80 citations Open access
Semantic Scholar
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
H. Rugo, S. Im, F. Cardoso, J. Cortés +30 more
2022Journal of Clinical Oncology75 citations Open access
Semantic Scholar
LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
G. Hortobagyi, S. Stemmer, H. Burris, Y. Yap +16 more
2021Annals of Oncology73 citations Open access
Semantic Scholar
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
S. Tolaney, A. Chan, K. Petráková, S. Delaloge +12 more
2023Journal of Clinical Oncology66 citations Open access
Semantic Scholar
Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.
F. Arena, S. Noguchi, K. Pritchard, H. Burris +16 more
2012Journal of Clinical Oncology65 citations
Semantic Scholar
Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results
I. Krop, S. Johnston, I. Mayer, M. Dickler +25 more
201557 citations
Semantic Scholar
First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study
C. Thomssen, J. Pierga, K. Pritchard, L. Biganzoli +5 more
2012Oncology55 citations
Semantic Scholar
Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).
G. Hortobagyi, S. Stemmer, H. Burris, Y. Yap +16 more
201752 citations
Semantic Scholar
Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
D. Slamon, P. Neven, S. Chia, P. Fasching +16 more
2019Annals of Oncology51 citations Open access
Semantic Scholar
Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
T. Tankova, E. Senkus, M. Beloyartseva, S. Borštnar +14 more
2022Cancers49 citations Open access
Semantic Scholar
A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane.
C. Twelves, D. Loesch, Joanne L. Blum, L. Vahdat +6 more
2010Journal of Clinical Oncology46 citations
Semantic Scholar
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
E. Hamilton, J. Cortés, O. Ozyılkan, Shin-Cheh Chen +11 more
2020Clinical Breast Cancer39 citations
Semantic Scholar
Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients.
P. Dobes, Ján Podhorec, O. Coufal, A. Jurečková +3 more
2014Oncology Report34 citations Open access
Semantic Scholar
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
F. Holmes, B. Moy, S. Delaloge, S. Chia +23 more
2023European Journal of Cancer33 citations Open access
Semantic Scholar
Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence
M. Holánek, I. Selingerová, O. Bílek, T. Kazda +9 more
2021Cancers33 citations Open access
Semantic Scholar
Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).
D. Slamon, P. Neven, S. Chia, G. Jerusalem +15 more
2021Journal of Clinical Oncology31 citations
Semantic Scholar
Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3
D. Slamon, P. Neven, S. Chia, S. Im +13 more
2018Geburtshilfe und Frauenheilkunde25 citations
Semantic Scholar
Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
D. Yardley, S. Noguchi, K. Pritchard, Howard A. Iii Burris +16 more
2014Advances in Therapy25 citations Open access
Semantic Scholar
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer
E. Hamilton, J. Cortés, O. Ozyılkan, Shin-Cheh Chen +8 more
2022Breast Cancer Research and Treatment21 citations Open access
Semantic Scholar
Abstract PD2-05: Biomarker analysis by baseline circulating tumor DNA alterations in the MONALEESA-3 study
P. Neven, K. Petráková, G. Bianchi, L. de la Cruz-Merino +10 more
2019Poster Discussion Abstracts20 citations
Semantic Scholar
Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
L. Foretova, M. Navratilova, M. Svoboda, P. Vasickova +7 more
2019Klinicka onkologie18 citations Open access
Semantic Scholar
Abstract PD4-06: First-line ribociclib + letrozole in hormone receptor-positive, HER2-negative advanced breast cancer: Efficacy by baseline circulating tumor DNA alterations in MONALEESA-2
G. Hortobagyi, S. Stemmer, M. Campone, G. Sonke +18 more
201818 citations
Semantic Scholar
First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses.
G. Hortobagyi, S. Paluch-Shimon, K. Petráková, C. Villanueva +13 more
201818 citations
Semantic Scholar
212MO AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC)
S. Tolaney, A. Chan, K. Petráková, S. Delaloge +9 more
2022Annals of Oncology17 citations Open access
Semantic Scholar
AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).
S. Chandarlapaty, H. Linden, P. Neven, K. Petráková +11 more
202117 citations
Semantic Scholar
LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)
P. Neven, P. A. Fasching, S. Chia, G. Jerusalem +14 more
2022Annals of Oncology16 citations Open access
Semantic Scholar
Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.
A. Poprach, O. Fiala, R. Chloupková, B. Melichar +11 more
2018Anticancer Research13 citations Open access
Semantic Scholar
Kardiovaskulární komplikace nádorů a jejich léčby
J. Vyskočil, K. Petráková, P. Jelínek, Michal Furdek
201813 citations
Semantic Scholar
Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers
F. André, S. Stemmer, M. Campone, K. Petráková +19 more
201713 citations
Semantic Scholar
Abstract S5-02: Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 3-year analysis from a phase 3 randomized, placebo-controlled, double-blind trial (ExteNET)
A. Chan, S. Delaloge, F. Holmes, B. Moy +19 more
201611 citations
Semantic Scholar
Combination Therapy of Lapatinib and Capecitabine forErbB2-Positive Metastatic or Locally Advanced BreastCancer: Results from the Lapatinib Expanded AccessProgram (LEAP) in Central and Eastern Europe
R. Greil, S. Borštnar, K. Petráková, Y. Marcou +7 more
2011Oncology Research and Treatment10 citations Open access
Semantic Scholar
Abstract P6-14-18: Updated Survival Analysis of a Phase III Study (EMBRACE) of Eribulin Mesylate Versus Treatment of Physician's Choice in Subjects with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane
C. Twelves, D. Loesch, J. Blum, L. Vahdat +6 more
201010 citations
Semantic Scholar
First-Line Bevacizumab (Bev) Combination Therapy in Triple-Negative (TN) Locally Recurrent/Metastatic Breast Cancer (LR/MBC): Subpopulation Analysis of Study MO19391 in >2000 Patients (Pts).
C. Thomssen, J. Pierga, K. Pritchard, L. Biganzoli +4 more
200910 citations
Semantic Scholar
Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis
H. Rugo, S. Im, F. Cardoso, J. Cortés +28 more
2022Cancer Research8 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Sonke×16
Invite
G. Sonke — researcher profile on SciRah
G. Hortobagyi×12
Invite
G. Hortobagyi — researcher profile on SciRah
A. Nusch×12
Invite
A. Nusch — researcher profile on SciRah
M. Campone×11
Invite
M. Campone — researcher profile on SciRah

×11

Invite

D. Yardley — researcher profile on SciRah

G. Jerusalem×11

Invite

G. Jerusalem — researcher profile on SciRah

Invite

P. Neven — researcher profile on SciRah

Invite

A. Chan — researcher profile on SciRah

Invite

T. Taran — researcher profile on SciRah

Invite

S. Stemmer — researcher profile on SciRah

Invite

E. Jakobsen — researcher profile on SciRah

Invite

S. Chia — researcher profile on SciRah